Tianjin Magnolia Shangde Biopharmaceutical Technology

PharmaOrigin (Tianjin Shangde Yaoyuan Technology) is a clinical-stage biopharmaceutical company based in Tianjin, China, specializing in the development of innovative small-molecule drugs for oncology and neurodegenerative diseases. The company's lead candidate, ACT001 (dimethylamino micheliolide), is a derivative of a natural sesquiterpene lactone that acts as an immunomodulator by inhibiting the NF-κB and STAT3 signaling pathways. ACT001 has received multiple orphan drug and fast-track designations globally and is currently in Phase 3 clinical trials for brain metastases from small cell lung cancer. PharmaOrigin focuses on addressing high unmet medical needs in the central nervous system and oncology sectors through its proprietary drug discovery and development capabilities.